Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

Trial Identifier: D5551R00012
Sponsor: AstraZeneca
Truven Health
NCTID:: NCT02843399
Start Date: August 2016
Primary Completion Date: December 2016
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
USA, DE Wilmington, DE, USA